Celgene raises 2017 forecast on cancer drugs, shares dip on near-term outlook
This article was originally published in Scrip
Executive Summary
Ceglene significantly raised its 2017 sales forecast on projected growth of Revlimid and other cancer drugs but gave a slightly lower than expected estimate for 2014.